In conclusion, patients with ER-poor and HER2-positive subtype of breast cancer are potential candidates for avoiding unnecessary axillary dissection due to its higher axillary node negative status rate after neoadjuvant chemo-trastuzumab therapy. This evidence concerns the gene ERBB2 and breast cancer.